Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms

Cancer Letters

Volumn 296, Issue 1, 2010, Pages 43-48

  Hellstrom, Ingegerd ^a   Heagerty, Patrick J ^a   Swisher, Elizabeth M ^a   Liu, Pu ^a   Jaffar, Jade ^a   Agnew, Kathy ^a   Hellstrom, Karl Erik ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ELISA; HE4; Ovarian cancer diagnostics; Urine

Indexed keywords

GLYCOPROTEIN; PROTEIN HE4; UNCLASSIFIED DRUG;

ARTICLE; BLOOD ANALYSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINALYSIS;

BIOLOGICAL MARKERS; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENITAL DISEASES, FEMALE; HUMANS; OVARIAN NEOPLASMS; POSTMENOPAUSE; PREMENOPAUSE; REFERENCE VALUES;

EID: 77954757517     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.03.013     Document Type: Article

References (32)

1. Kobel M., Kalloger S.E., Boyd N., McKinney S., Mehl E., Palmer C., Leung S., Bowen N.J., Ionescu D.N., Rajput A., Prentice L.M., Miller D., Santos J., Swenerton K., Gilks C.B., Huntsman D. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008, 5:e232.
2. Brown P.O., Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009, 6:e1000114.
3. Kurman R.J., Visvanathan K., Roden R., Wu T.C., Shih I. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am. J. Obstet. Gynecol. 2008, 198:351-356.
4. Jacobs I., Bast J.R.C. The CA-125 tumour associated antigen: a review of the literature. Hum. Reprod. 1989, 4:1-12.
5. Maggino T., Gadducci A., D'Addario V., Pecorelli S., Lissoni A., Stella M., Romagnolo C., Federghini M., Zucca S., Trio D., Trovò S. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol. Oncol. 1994, 54:117-123.
6. Berek J.S., Bast J.R.C. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995, 76:2092-2096.
7. Partridge E., Kreimer A.R., Greenle R.T., Williams C., Xu J.L., Church T.R., Kessel B., Johnson C.C., Weissfeld J.L., Isaacs C., Andriole G.L., Ogden S., Ragard L.R., Buys S.S. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol. 2009, 113:775-782.
8. Chang K., Pai L.H., Batra J.K., Pastan I., Willingham M.C. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 1992, 52:181-186.
9. Chang K., Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 1996, 93:136-140.
10. Scholler N., Fu N., Yang Y., Ye Z., Goodman G.E., Hellström K.E., Hellström I. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. USA 1999, 96:11531-11536.
11. Hellstrom I., Raycraft J., Kanan S., Sardesai N.Y., Verch T., Yang Y., Hellstrom K.E. Mesothelin-variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol. Biomark. Prev. 2006, 15:1014-1020.
12. McIntosh M.W., Drescher C., Karlan B., Scholler N., Urban N., Hellstrom K.E., Hellstrom I. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol. 2004, 95:9-15.
13. Shah C.A., Lowe K.A., Paley P.J., Wallace E., Anderson G.L., McIntosh M.W., Andersen M.R., Scholler N., Bergan L.A., Thorpe J.D., Urban N., Drescher C.W. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol. Biomark. Prev. 2009, 18:1365-1372.
14. Robinson B.W.S., Creaney J., Lake R.L., Nowak A., Musk A.W., de Klerk N., Winzell P., Hellstrom K.E., Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362:1612-1616.
15. Kirchoff C., Habben I., Ivell R., Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitor. Biol. Reprod. 1991, 45:350-357.
16. Wang K., Gan L., Jeffrey E., Gayle M., Gown A.M., Skelly M., Nelson P.S., Ng W.V., Schummer M., Hood L., Mulligan J. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999, 229:101-108.
17. Schummer M., Ng W., Bumgarner R., Nelson P.S., Schummer B., Bednarski D.W., Hassell L., Baldwin R.L., Karlan B.Y., Hood L. Comparative hybridization of an array of 21500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999, 238:375-385.
18. Ono K., Tanaka T., Tsunoda T., Kitahara O., Kihara C., Okamoto A., Ochiai K., Takagi T., Nakamura Y. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res. 2000, 60:5007-5011.
19. Galgano M.T., Hampton G.M., Frierson H.F.J. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod. Pathol. 2006, 19:847-853.
20. Bingle L., Cross S., High A.S., Wallace W.A., Rassl D., Yuan G., Hellstrom I., Campos M.A., Bingle C.D. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract in the development of adenocarcinomas of the lung. Respir. Res. 2006, 7:61-80.
21. Dandekar A.M., Robinson E.A., Appellla E., Qasba P.K. Complete sequence analysis of cDNA clones encoding rat whey phosphoprotein: homology to a protease inhibitor. Proc. Natl. Acad. Sci. USA 1982, 79:3987-3991.
22. Heinzel R., Appelhans H., Gassen G., Seemüller U., Machleidt W., Fritz H., Steffens G. Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus. Eur. J. Biochem. 1986, 160:61-67.
23. Wiedow O., Schroder J.M., Gregory H., Young J.A., Christophers E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem. 1990, 265:14791-14795.
24. Hellstrom I., Raycraft J., Hayden-Ledbetter M., Schummer M., McIntosh M., Drescher C., Urban N., Hellström K.E. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63:3695-3700.
25. Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., Steinhoff M., Messerlian G., DiSilvestro P., Granai C.O., Bast J.R.C. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 2008, 108:402-408.
26. Moore R.G., McMeekin D.S., Brown A.K., DiSilvestro P., Miller M.C., Allard W.J., Gajewski W., Kurman R., Bast J.R.C., Skates S.J. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009, 112:40-46.
27. Palmer C., Duan X., Hawley S., Scholler N., Thorpe J.D., Sahota R.A., Wong M.Q., Wray A., Bergan L.A., Drescher C.W., McIntosh M.W., Brown P.O., Nelson B.H., Urban N. Systemic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One 2008, 3:e2633.
28. Ye B., Skates S., Mok S.C., Horick N.K., Rosenberg H.F., Vitonis A., Edwards D., Sluss P., Han W.K., Berkowitz R.S., Cramer D.W. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 2006, 12:432-441.
29. Badgwell D., Lu Z., Cole L., Fritsche H., Atkinson E.N., Somers E., Allard J., Moore R.G., Lu K.H., Bast J.R.C. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol. Oncol. 2008, 106:490-497.
30. Anderson N.S., Bermudez Y., Badgwell D., Chen R., Nicosia S.V., Bast J.R.C., Kruk P.A. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol. Oncol. 2009, 112:60-67.
31. Steyerberg E., Harrrell F.J., Borsboom G.J., Eijkemans M.J., Vergouwe Y., Habbema J.D. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J. Clin. Epidemiol. 2001, 54:774-781.
32. Bast J.R.C. Status of tumor markers in ovarian cancer screening. J. Clin. Oncol. 2003, 21(10 Suppl.):200-205.